Click on the logos for more information.
Leverages cutting-edge technology and biology using repurposed FDA-approved drugs to deliver accelerated, off-label treatments for various types of CMT.
Pioneering Next Generation HDAC6i’s to advance life-changing disease cures for CMT patients and other peripheral neuropathies.
Clinical-stage biopharmaceutical company, partnered with HNF in 2012 to support the development of PXT3003. the protein impacted in CMT1A.
Clinical-stage biopharmaceutical company conducting a trial for patients with Sorbitol Dehydrogenase (SORD) Deficiency.